The Food and Drug Administration has approved the first new kind of drug to treat depression since Prozac hit the scene in the late 1980s. Spravato is a nasal spray from Johnson & Johnson that’s a close cousin of ketamine, an anesthetic that’s sometimes used recreationally and often known as “Special K.” Because ketamine can cause hallucinations and out-of-body experiences, the new drug must be administered in a clinical setting. The drug is designed to start working in hours instead of weeks. It’s meant to treat people who have not found relief through other antidepressants. That’s about 5 million of the 16 million Americans with depression.
Click the audio player above to hear the full story.
Correction (March 6, 2019): A previous version of this story misspelled Spravato. The text has been corrected.
We’re here to help you navigate this changed world and economy.
Our mission at Marketplace is to raise the economic intelligence of the country. It’s a tough task, but it’s never been more important.
In the past year, we’ve seen record unemployment, stimulus bills, and reddit users influencing the stock market. Marketplace helps you understand it all, will fact-based, approachable, and unbiased reporting.
Generous support from listeners and readers is what powers our nonprofit news—and your donation today will help provide this essential service. For just $5/month, you can sustain independent journalism that keeps you and thousands of others informed.